Tefibazumab
Alternative Names: S. aureus monoclonal antibody - Inhibitex; Staphylococcus aureus monoclonal antibody - Inhibitex; Aurexis; Humanised mAb 12-9 - Inhibitex; INH-H2002Latest Information Update: 02 Oct 2021
At a glance
- Originator Inhibitex
- Class Antibacterials; Antitoxins; Monoclonal antibodies
- Mechanism of Action Cell adhesion molecule inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Staphylococcal infections
Most Recent Events
- 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
- 22 Nov 2010 Tefibazumab is available for licensing as of 22 Nov 2010. http://www.inhibitex.com
- 21 Aug 2007 Tefibazumab is available for licensing (http://www.inhibitex.com)